or
forgot password

A Randomized Phase 2 Trial Of PF-00299804 Versus Erlotinib For The Treatment Of Advanced Non Small Cell Lung Cancer After Failure Of At Least One Prior Chemotherapy Regimen


Phase 2
18 Years
N/A
Open (Enrolling)
Both
Non-small Cell Lung Cancer

Thank you

Trial Information

A Randomized Phase 2 Trial Of PF-00299804 Versus Erlotinib For The Treatment Of Advanced Non Small Cell Lung Cancer After Failure Of At Least One Prior Chemotherapy Regimen


Inclusion Criteria:



- advanced measurable Non-Small Cell Lung Cancer (NSCLC);

- progressed after 1-2 prior chemotherapy;

- Eastern Cooperative Oncology Group (ECOG) 0-2;

- tissue available for future KRAS/ EGFR testing

Exclusion Criteria:

- prior Epidermal Growth Factor Receptor (EGFR) targeted therapy;

- active or untreated Central Nervous System (CNS) metastases;

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression- Free Survival for patients in each arm

Outcome Time Frame:

13 months

Safety Issue:

No

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

A7471028

NCT ID:

NCT00769067

Start Date:

November 2008

Completion Date:

December 2013

Related Keywords:

  • Non-Small Cell Lung Cancer
  • Lung cancer
  • advanced
  • second or third line
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location
Pfizer Investigational Site Birmingham, Alabama  35205
Pfizer Investigational Site Blendora, California  91740
Pfizer Investigational Site Atlanta, Georgia  30342
Pfizer Investigational Site Rochester, Minnesota  55905
Pfizer Investigational Site Springfield, Illinois  62701-1014
Pfizer Investigational Site Westminster, Maryland  21157
Pfizer Investigational Site Farmington, Connecticut  06030-3805
Pfizer Investigational Site Bristol, Tennessee  37620
Pfizer Investigational Site Olive Branch, Mississippi  38654
Pfizer Investigational Site Lewistown, Idaho  83501
Pfizer Investigational Site Morgantown, West Virginia  26506